A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon-like peptide-1 receptor agonist therapy.

Autor: Knop FK; Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.; Steno Diabetes Center Copenhagen, Herlev, Denmark., Urva S; Eli Lilly and Company, Indianapolis, Indiana, USA., Rettiganti M; Eli Lilly and Company, Indianapolis, Indiana, USA., Benson CT; Eli Lilly and Company, Indianapolis, Indiana, USA., Roell WC; Eli Lilly and Company, Indianapolis, Indiana, USA., Mather KJ; Eli Lilly and Company, Indianapolis, Indiana, USA., Haupt A; Eli Lilly and Company, Indianapolis, Indiana, USA., Pratt EJ; Eli Lilly and Company, Indianapolis, Indiana, USA.

Publikováno v: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2024 Nov; Vol. 26 (11), pp. 5474-5478. Date of Electronic Publication: 2024 Aug 27.

Elevated circulating follistatin associates with an increased risk of type 2 diabetes.

Autor: Wu C; Department of Clinical Sciences, Lund University, Malmö, Sweden.; School of Control Science and Engineering, Shandong University, Jinan, Shandong, China.; School of Intelligent Engineering, Shandong Management University, Jinan, Shandong, China., Borné Y; Department of Clinical Sciences, Lund University, Malmö, Sweden., Gao R; School of Control Science and Engineering, Shandong University, Jinan, Shandong, China., López Rodriguez M; Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland, Kuopio, Finland.; A.I. Virtanen Institute for Molecular Sciences, Department of Biotechnology and Molecular Medicine, University of Eastern Finland, Kuopio, Finland., Roell WC; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA., Wilson JM; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA., Regmi A; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA., Luan C; Department of Clinical Sciences, Lund University, Malmö, Sweden., Aly DM; Department of Clinical Sciences, Lund University, Malmö, Sweden., Peter A; Department of Internal Medicine IV, Division of Endocrinology, Diabetology and Nephrology; and Department for Diagnostic Laboratory Medicine, Institute for Clinical Chemistry and Pathobiochemistry, University Hospital Tübingen, University of Tübingen, Tübingen, Germany.; Institute of Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich, Tübingen, Germany.; German Center for Diabetes Research (DZD), Tübingen, Germany., Machann J; Institute of Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich, Tübingen, Germany.; German Center for Diabetes Research (DZD), Tübingen, Germany.; Section of Experimental Radiology, Department of Radiology, University of Tübingen, Tübingen, Germany., Staiger H; Department of Internal Medicine IV, Division of Endocrinology, Diabetology and Nephrology; and Department for Diagnostic Laboratory Medicine, Institute for Clinical Chemistry and Pathobiochemistry, University Hospital Tübingen, University of Tübingen, Tübingen, Germany.; Institute of Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich, Tübingen, Germany.; German Center for Diabetes Research (DZD), Tübingen, Germany., Fritsche A; Department of Internal Medicine IV, Division of Endocrinology, Diabetology and Nephrology; and Department for Diagnostic Laboratory Medicine, Institute for Clinical Chemistry and Pathobiochemistry, University Hospital Tübingen, University of Tübingen, Tübingen, Germany.; Institute of Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich, Tübingen, Germany.; German Center for Diabetes Research (DZD), Tübingen, Germany., Birkenfeld AL; Department of Internal Medicine IV, Division of Endocrinology, Diabetology and Nephrology; and Department for Diagnostic Laboratory Medicine, Institute for Clinical Chemistry and Pathobiochemistry, University Hospital Tübingen, University of Tübingen, Tübingen, Germany.; Institute of Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich, Tübingen, Germany.; German Center for Diabetes Research (DZD), Tübingen, Germany., Tao R; Division of Endocrinology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA., Wagner R; Department of Internal Medicine IV, Division of Endocrinology, Diabetology and Nephrology; and Department for Diagnostic Laboratory Medicine, Institute for Clinical Chemistry and Pathobiochemistry, University Hospital Tübingen, University of Tübingen, Tübingen, Germany.; Institute of Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich, Tübingen, Germany.; German Center for Diabetes Research (DZD), Tübingen, Germany., Canouil M; Inserm U1283 / CNRS UMR 8199, European Genomic Institute for Diabetes (EGID), Institut Pasteur de Lille; University of Lille, Lille University Hospital, Lille, France., Hong MG; Affinity Proteomics, Science for Life Laboratory, KTH Royal Institute of Technology, Stockholm, Sweden., Schwenk JM; Affinity Proteomics, Science for Life Laboratory, KTH Royal Institute of Technology, Stockholm, Sweden., Ahlqvist E; Department of Clinical Sciences, Lund University, Malmö, Sweden., Kaikkonen MU; A.I. Virtanen Institute for Molecular Sciences, Department of Biotechnology and Molecular Medicine, University of Eastern Finland, Kuopio, Finland., Nilsson P; Department of Clinical Sciences, Lund University, Malmö, Sweden., Shore AC; NIHR Exeter Clinical Research Facility, Royal Devon and Exeter Hospital and University of Exeter Medical School, Exeter, Devon, UK., Khan F; Division of Systems Medicine, University of Dundee, Ninewells Hospital & Medical School, Dundee, UK., Natali A; Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy., Melander O; Department of Clinical Sciences, Lund University, Malmö, Sweden., Orho-Melander M; Department of Clinical Sciences, Lund University, Malmö, Sweden., Nilsson J; Department of Clinical Sciences, Lund University, Malmö, Sweden., Häring HU; Department of Internal Medicine IV, Division of Endocrinology, Diabetology and Nephrology; and Department for Diagnostic Laboratory Medicine, Institute for Clinical Chemistry and Pathobiochemistry, University Hospital Tübingen, University of Tübingen, Tübingen, Germany.; Institute of Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich, Tübingen, Germany.; German Center for Diabetes Research (DZD), Tübingen, Germany., Renström E; Department of Clinical Sciences, Lund University, Malmö, Sweden., Wollheim CB; Department of Clinical Sciences, Lund University, Malmö, Sweden.; Department of Cell Physiology and Metabolism, University Medical Centre, Geneva, Switzerland., Engström G; Department of Clinical Sciences, Lund University, Malmö, Sweden., Weng J; Department of Endocrinology and Metabolism, Division of Life Sciences of Medicine, University of Science and Technology of China, Hefei, China., Pearson ER; Division of Population Health & Genomics, School of Medicine, University of Dundee, Dundee, DD1 9SY, UK., Franks PW; Department of Clinical Sciences, Lund University, Malmö, Sweden., White MF; Division of Endocrinology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA., Duffin KL; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA., Vaag AA; Steno Diabetes Center Copenhagen, Gentofte, Denmark., Laakso M; Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland, Kuopio, Finland.; Department of Medicine, Kuopio University Hospital, Kuopio, Finland., Stefan N; Department of Internal Medicine IV, Division of Endocrinology, Diabetology and Nephrology; and Department for Diagnostic Laboratory Medicine, Institute for Clinical Chemistry and Pathobiochemistry, University Hospital Tübingen, University of Tübingen, Tübingen, Germany.; Institute of Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich, Tübingen, Germany.; German Center for Diabetes Research (DZD), Tübingen, Germany., Groop L; Department of Clinical Sciences, Lund University, Malmö, Sweden.; Finnish Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland., De Marinis Y; Department of Clinical Sciences, Lund University, Malmö, Sweden. yang.de_marinis@med.lu.se.; School of Control Science and Engineering, Shandong University, Jinan, Shandong, China. yang.de_marinis@med.lu.se.; Department of Endocrinology and Metabolism, Division of Life Sciences of Medicine, University of Science and Technology of China, Hefei, China. yang.de_marinis@med.lu.se.

Publikováno v: Nature communications [Nat Commun] 2021 Nov 10; Vol. 12 (1), pp. 6486. Date of Electronic Publication: 2021 Nov 10.

Angiopoietin-like protein 4(E40K) and ANGPTL4/8 complex have reduced, temperature-dependent LPL-inhibitory activity compared to ANGPTL4.

Autor: Chen YQ; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA., Pottanat TG; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA; Department of Biology, Indiana University - Purdue University Indianapolis, Indianapolis, IN, USA., Siegel RW; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA., Ehsani M; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA., Qian YW; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA., Roell WC; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA., Konrad RJ; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA. Electronic address: konrad_robert@lilly.com.

Publikováno v: Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2021 Jan 01; Vol. 534, pp. 498-503. Date of Electronic Publication: 2020 Nov 22.

Angiopoietin-like protein 8 differentially regulates ANGPTL3 and ANGPTL4 during postprandial partitioning of fatty acids.

Autor: Chen YQ; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN., Pottanat TG; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN., Siegel RW; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN., Ehsani M; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN., Qian YW; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN., Zhen EY; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN., Regmi A; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN., Roell WC; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN., Guo H; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN., Luo MJ; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN., Gimeno RE; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN., Van't Hooft F; Division of Cardiovascular Medicine, Department of Medicine Solna, Karolinska Institutet Karolinska University Hospital Solna, Stockholm, Sweden., Konrad RJ; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN konrad_robert@lilly.com.

Publikováno v: Journal of lipid research [J Lipid Res] 2020 Aug; Vol. 61 (8), pp. 1203-1220. Date of Electronic Publication: 2020 Jun 02.

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.

Autor: Coskun T; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Sloop KW; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Loghin C; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Alsina-Fernandez J; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Urva S; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Bokvist KB; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Cui X; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Briere DA; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Cabrera O; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Roell WC; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Kuchibhotla U; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Moyers JS; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Benson CT; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Gimeno RE; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., D'Alessio DA; Division of Endocrinology, Metabolism, and Nutrition, Duke University Medical Center, Durham, NC, USA., Haupt A; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA. Electronic address: haupt_axel@lilly.com.

Publikováno v: Molecular metabolism [Mol Metab] 2018 Dec; Vol. 18, pp. 3-14. Date of Electronic Publication: 2018 Oct 03.